Literature DB >> 19070823

[Pain and bone metastases].

J Wassermann1, B De La Lande, A Pecking, L Brasseur.   

Abstract

Average 20% of the cancer patients will have bone metastasis most of time painful and with variable clinical expressions. Due to animal models, the bone metastasis pain is better known and it explains the different treatments mechanisms. After a suitable evaluation of the pain, several therapeutic approaches can be suggested. In addition to the classical analgesics, several medications are known to be efficient in few indications like neuropathic pain. Besides a local surgery, an external radiotherapy or an interventional radiology treatment can often be useful along with a medical treatment. When there is a bone progression, the anti-cancer treatment by chemotherapy, hormonotherapy or targeted therapies must always be reviewed, because if efficient it could have an analgesic action.

Entities:  

Mesh:

Year:  2008        PMID: 19070823     DOI: 10.1016/S1166-7087(08)74574-3

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  3 in total

1.  Cementoplasty for painful bone metastases: a series of 42 cases.

Authors:  Estelle Botton; Julien Edeline; Yan Rolland; Elodie Vauléon; Catherine Le Roux; Habiba Mesbah; Philippe Porée; Odile Audrain; Jean-Luc Raoul
Journal:  Med Oncol       Date:  2011-04-17       Impact factor: 3.064

2.  The Roles of Magnetic Resonance-Guided Focused Ultrasound in Pain Relief in Patients With Bone Metastases: A Systemic Review and Meta-Analysis.

Authors:  Xiaying Han; Runzhi Huang; Tong Meng; Huabin Yin; Dianwen Song
Journal:  Front Oncol       Date:  2021-08-11       Impact factor: 6.244

3.  Magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: role of apparent diffusion coefficient (ADC) and dynamic contrast enhanced (DCE) MRI in the assessment of clinical outcome.

Authors:  Michele Anzidei; Alessandro Napoli; Beatrice Sacconi; Fabrizio Boni; Vincenzo Noce; Michele Di Martino; Luca Saba; Carlo Catalano
Journal:  Radiol Med       Date:  2016-08-27       Impact factor: 3.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.